Skip to main content

Table 2 Frequency distributions of investigated markers among different studied groups

From: Impact of circulating miRNA-373 on breast cancer diagnosis through targeting VEGF and cyclin D1 genes

Groups

Markers

VEGF (fold change)

Cyclin D1 (fold change)a

miR-373 (fold change)a

Mean ranka

≤ 38b

> 38

Mean ranka

≤ 38

> 38

Mean ranka

≤ 360

> 360

Healthy individuals

32.86

49 (100%)

0 (0%)

30.92

49 (100%)

0 (0%)

27.04

49 (100%)

0 (0%)

Benign lesions

88.78

73 (96.1%)

3 (3.9%)

91.59

72 (94.7%)

4 (5.3%)

92.57

75 (98.7%)

1 (1.3%)

Primary breast cancer

221.05

14 (7.1%)

182 (92.9%)

220.43

16 (8.2%)

180 (91.8%)

221.03

17 (8.7%)

179 (91.3%)

  1. aAnalysis using non-parametric mean rank test by Kruskal-Wallis test (as to calculate the average of the ranks for the marker among the enrolled groups)
  2. bChi-square test with statistical significance at P< 0.0001